^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

BIRC5 expression

i
Other names: BIRC5, API4, EPR-1, survivin, Baculoviral IAP repeat containing 5
Entrez ID:
Related biomarkers:
1year
Antitumor Effect of Bromo-Naphthoquinone Associated with Tannic Acid in Triple Negative Breast Cancer Cells. (PubMed, Int J Biochem Cell Biol)
Furthermore, relevant changes were detected in the expression of Bcl-2, BAX, FAS, and BIRC-5, while no significant alteration in the expression of NOXs was observed. In conclusion, our findings suggested that the combination of BrNQ and TA though the ability to change redox status in tumor cells could act as a potential adjuvant treatment modality for improve prognosis in TNBC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein)
|
BCL2 expression • BIRC5 expression • BAX expression
1year
Old Passengers as New Drivers: Chromosomal Passenger Proteins Engage in Translesion Synthesis. (PubMed, Cells)
In this study, we assigned a direct function to the CPC in the transition from stalled replication forks to translesion synthesis, further emphasizing the ubiquitous overexpression of Survivin particularly in tumors. This study, for the first time, assigns a direct function to the chromosomal passenger complex, CPC, including Survivin, Aurora B kinase, Borealin, and INCENP, in the transition from stalled replication forks (involving PCNA binding) to translesion synthesis (liberating Pol η by phosphorylating POLDIP2), and thus in maintaining genomic integrity.
Journal
|
POLD1 (DNA Polymerase Delta 1) • BIRC5 (Baculoviral IAP repeat containing 5) • PCNA (Proliferating cell nuclear antigen) • CDCA8 (Cell Division Cycle Associated 8)
|
BIRC5 expression • BIRC5 overexpression
1year
Inhibition of Chk1 with Prexasertib Enhances the Anticancer Activity of Ciclopirox in Non-Small Cell Lung Cancer Cells. (PubMed, Cells)
This was associated with increased expression of DR4, DR5, Fas, and FADD and decreased expression of survivin, resulting in activation of caspase 8 and caspase 3 as well as cleavage of poly (ADP ribose) polymerase (PARP). Taken together, the results suggest that inhibition of Chk1 with PRE can enhance the anticancer activity of CPX at least partly by decreasing cell proliferation and increasing apoptosis in NSCLC cells.
Journal • PARP Biomarker
|
CDK4 (Cyclin-dependent kinase 4) • BIRC5 (Baculoviral IAP repeat containing 5) • CDK6 (Cyclin-dependent kinase 6) • CHEK1 (Checkpoint kinase 1) • FADD (Fas associated via death domain) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CDK2 (Cyclin-dependent kinase 2) • CDC25C (Cell Division Cycle 25C) • CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1)
|
BIRC5 expression
|
prexasertib (ACR-368)
1year
Survivin promotes stem cell competence for skin cancer initiation. (PubMed, Cancer Discov)
We identified SGK1, as a key downstream factor of Survivin, and its inhibition prevents BCC formation. This study uncovers the role and mechanisms by which Survivin regulates the competence of SCs to initiate BCC formation promoting the survival of oncogene-expressing SCs and self-renewing division while restricting differentiation and apoptosis.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
1year
Cationic Metal-Organic Layer Delivers siRNAs to Overcome Radioresistance and Potentiate Cancer Radiotherapy. (PubMed, Angew Chem Int Ed Engl)
The CMOL@siRNA nanoplatform not only increased energy deposition from X-rays and reactive oxygen species generation via a unique radiotherapy-radiodynamic therapy process, but also effectively delivered siRNAs to downregulate survivin expression and ameliorate radioresistance of cancer cells. Consequently, CMOL@siRNA in combination with low-dose X-ray irradiation demonstrated remarkable antitumor efficacy with 96.9% and 91.4% tumor growth inhibition in murine colorectal carcinoma and triple-negative breast cancer models, respectively.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
1year
Triple-regulated conditionally replicating adenovirus for effective and safer treatment of peritoneal carcinomatosis. (PubMed, Biochem Biophys Res Commun)
In conclusion, the triple-regulated Surv.m-CRA-CEAp enhances cancer specificity (i.e., safety) without reducing the potent therapeutic effect for carcinoembryonic antigen-positive gastric cancer-derived peritoneal carcinomatosis. The modified E1B promoter strategy of CRA facilitates the development of novel CRAs for the effective and safe treatment of a variety of refractory cancers.
Journal
|
CEACAM5 (CEA Cell Adhesion Molecule 5) • BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • CEACAM5 positive
1year
Mechanism of Huayu Jiedu Decoction in Inhibiting Malignant Biological Characteristics of Multiple Myeloma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
Huayu Jiedu Decoction can inhibit the proliferative activity of U266 cells and induce programmed death. Its molecular mechanism may be related to regulating the expression of apoptotic proteins, inhibiting the activation of TLR4/NF-κB pathway and down-regulating the expression of HMGB1 and IL-6 mRNA.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IL6 (Interleukin 6) • BIRC5 (Baculoviral IAP repeat containing 5) • BAX (BCL2-associated X protein) • HMGB1 (High Mobility Group Box 1) • ANXA5 (Annexin A5)
|
BCL2 expression • BIRC5 expression • BAX expression • CXCR4 expression • IL6 expression
1year
Compound #41 Targets Acute Myelogenous Leukemia by Inhibiting the Wnt/β-catenin Signaling Pathway. (PubMed, Anticancer Res)
Compound #41 suppressed the Wnt/β-catenin signaling pathway by reducing CTNNB1 levels and induced apoptosis in AML cells. Furthermore, compound #41 inhibited the proliferation of KG1a-Luc/GFP cells in the bone marrow and extended the overall survival of mice. Thus, compound #41 is an attractive Wnt/β-catenin signaling pathway inhibitor of AML.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
1year
Peptide-Based Turn-On Fluorescent Probes for Highly Specific Detection of Survivin Protein in the Cancer Cells. (PubMed, Chem Biomed Imaging)
Confocal fluorescence imaging demonstrated that SSFP5 exhibited clear fluorescence signals in survivin-positive MDA-MB-231 cells, whereas no marked fluorescence signals were observed in survivin-negative MCF-10A cells. Collectively, these results suggest that SSFPs can be used as survivin-specific FRET imaging probes.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression • BIRC5 overexpression
1year
The prognostic role of survivin expression in breast cancer: A systematic review and meta-analysis. (PubMed, Medicine (Baltimore))
In this study, we evaluated the prognostic significance of survivin expression in patients with breast cancer through a meta-analysis. These results support the use of survivin expression as a prognostic marker in breast cancer, potentially guiding treatment decisions.
Clinical • Retrospective data • Review • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
1year
Correlation Between Tumor Budding and Survivin Expression in Colorectal Cancer. (PubMed, Clin Exp Gastroenterol)
The expression level of Survivin was significantly correlated with TNM stage, lymph node metastasis and distant metastasis in patients with colorectal cancer; tumor outgrowth was significantly correlated with TNM stage, lymph node metastasis and distant metastasis in patients with colorectal cancer (P < 0.05); the expression level of Survivin was significantly correlated with the degree of tumor budding in patients with colorectal cancer (P < 0.05). In this paper, we tested the relationship between Survivin and tumor budding in colon cancer, and analyzed its relationship with clinicopathological features, with a view to providing a reference for the mechanism related to colorectal cancer.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
BIRC5 expression
1year
A Bioinformatics-Based Approach to Discover Novel Biomarkers in Hepatocellular Carcinoma. (PubMed, Iran J Public Health)
Identifying potential biomarkers for LIHC can aid in the design of targeted treatments and improve the survival of LIHC patients. The findings of this study provide a basis for further research in the field of LIHC and contribute to the understanding of its molecular pathogenesis.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • CCNA2 (Cyclin A2) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • NCAPG (Non-SMC Condensin I Complex Subunit G) • CCNB1 (Cyclin B1) • CENPF (Centromere Protein F) • KIF20A (Kinesin Family Member 20A)
|
BIRC5 expression